Skip to main content
SpringerLink
Log in

C-reactive protein as an acute phase protein in cancer patients

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aim of our study was to determine the rate of elevation of c-reactive protein in cancer patients and to evaluate its correlation with other acute phase proteins. A total of 104 patients with various types of cancer who admitted clinic were included in our study. Serum levels of c-reactive protein, lactate dehydrogenase, ferritin, haptoglobin, plasma fibrinogen levels and erythyrocyte sedimentation rate were measured. The serum levels of c-reactive protein was found to be increased in 74% of cancer patients, with 81.3% and 64.4% in metastatic and non-metastatic group, respectively. Our study showed that c-reactive protein and fibrinogen demonstrated better characteristics than other acute phase proteins to differentiate between cancer patients and healthy individuals and also to differentiate between healthy individuals and patients with infection. C-reactive protein, ferritin, fibrinogen, erythrocyte sedimentation rate, and haptoglobin showed similar characteristics to differentiate metastatic and non-metastatic cancer patients whereas, LDH demonstrated the lowest performance. C-reactive protein was not found to be superior to other acute phase proteins in the differential diagnosis of cancer and infection and in differentiating early stage disease from advanced stage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Koc M, Taysi S, Sezen O, Bakan N. Levels of some acute-phase proteins in the serum of patients with cancer during radiotherapy. Biol Pharm Bull 2003;26(10):1494–7.

    Article  PubMed  CAS  Google Scholar 

  2. Mcmillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003;90(2):215–9.

    Article  PubMed  CAS  Google Scholar 

  3. Zhang S, Buring J, Lee I, Cook N, Ridker P. C-rective protein levels are not associated with increased risk colorectal cancer in women. Ann Intern Med 2005;142(6):425–33.

    PubMed  CAS  Google Scholar 

  4. Wigmore SJ, McMahon AJ, Sturgeon CM, Fearon KCH. Acute phase protein response, survival and tumour recurrence in patients with colorectal cancer. Br J Surg 2001;88(2):255–60.

    Article  PubMed  CAS  Google Scholar 

  5. Wieland A, Kerbl R, Berghold A, Schwinger W, Mann G, Urban C. C-Reactive protein as tumor marker in pediatric and adolescent patients with Hodgkin disease. Med Pediatr Oncol. 2003;41(1):21–5.

    Article  PubMed  Google Scholar 

  6. Kallio R, Bloigu A, Surcel HM, Syrjala H. C-reactive protein and erythrocyte sedimentation rate in differential diagnosis between infections and neoplastic fever in patients with solid tumors and lymphomas Support Care Cancer 2001;9(2):124–8.

    Article  PubMed  CAS  Google Scholar 

  7. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation serum c-reactive protein as an indicator for indicator for prognosis in colorectal cancer Am J Surg 1998;176(4):335–8.

    Article  PubMed  CAS  Google Scholar 

  8. Koenig W, Sund M, Fröchlich M, Fischer H, Löwel H, Döring A, Hutchinson W, Pepys M. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle aged men Circulation 1999;99(2):237–42.

    PubMed  CAS  Google Scholar 

  9. Nikiteas N, Tzanakis N, Gazouli M, Rallis G, Danilidis K, Theodoropulos G, Kostakis A, Peros G. Serum IL-6, TNF-α and CRP levels in colorectal cancer patients: prognostic implications World J Gastroenterol 2005;11(11):1639–43.

    PubMed  CAS  Google Scholar 

  10. Child JA, Cooper EH, Ilingworth S. Biochemical markers in Hodgkin’s disease and non-Hodgkin lymphoma Recent results Cancer Res 1978;64:180–9.

    PubMed  CAS  Google Scholar 

  11. Legouffe E, Rodriguez C, Picot MC. C reactive protein serum level is valuable and simple prognostic marker in non-Hodgkin lymphoma Leuk Lymphoma 1998;31(3–4):351–7.

    PubMed  CAS  Google Scholar 

  12. Tartour E, Deneux L, Mosseri V. Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results multivariate prospective study Cancer 1997;79(7):1401–8.

    Article  PubMed  CAS  Google Scholar 

  13. Nakano T, Chanabian AP, Shinjo M. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma Br J Cancer 1998;77(6):907–12.

    PubMed  CAS  Google Scholar 

  14. Inoue T, Hashimura T, Iwamura H. Multivariate analysis of prognostic analysis of prognostic determinants after surgery for renal cell carcinoma at Himeji National Hospital. Hinyokika Kiyo 2000;46(4):229–34.

    PubMed  CAS  Google Scholar 

  15. Masuda H, Kurita Y, Fukuta K. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int J Urol 1998;5(5):418–22.

    Article  PubMed  CAS  Google Scholar 

  16. Wechsel HW, Feil G, Lahme S. Control of hepatic parameters in renal cell carcinoma by interleukin-6? Anticancer Res 1999;19(4A):2577–81.

    PubMed  CAS  Google Scholar 

  17. Zaloudik J, Lauerova L, Janakova L. Significance of pretreatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver. Hepatogastroenterology 1999;46(25):220–7.

    PubMed  CAS  Google Scholar 

  18. Barber MD, Powell JJ, Lynch SF. Two polymorphisms of tumor necrosis factor gene do nor influence survival in pancreatic cancer Clin Exp Immunol 1999;117(3):425–9.

    Article  PubMed  CAS  Google Scholar 

  19. Ljunberg B, Grankvist K, Rasmuson T. Serum Interleukin -6 in Relation to Acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 1997;33(11):1794–8.

    Article  Google Scholar 

  20. Bien E, Balcerska A. Clinical significance of erythrocyte sedimentation rate, C reactive protein and serum lactate dehydrogenase levels in the diagnosis, prognosis and treatment monitoring of children suffering from cancer. Med Wieku Rozwoj, 2004;8(4):1081–9.

    Google Scholar 

  21. Latif Z, Mcmillan DC, Wallace AM, Sattar N, Mir K, Jones G. The relationship of circulating insulin like growth factor 1, its binding protein-3, prostate specific antigen and C-reactive protein with disease stage in prostate cancer BJU International 2002;89(4):396–9.

    Article  PubMed  CAS  Google Scholar 

  22. Salawu L, Durosinmi MA. Erythrocyte sedimentation rate and plasma viscosity in health and disease. Niger J Med 2001;10(1):11–3.

    PubMed  CAS  Google Scholar 

  23. Alexandrakis MG, Passam FH, Ganotakis ES, Sfiridaki K, Xilouri I, Perinakis K, Kyriaoku DS. The clinical and prognostic significance of erythrocyte sedimentation rate(ESR), serum interleukin -6(IL-6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol 2003;25(1):41–6.

    Article  PubMed  CAS  Google Scholar 

  24. Miyata Y, Shigehiko K, Nishikido M, Noguchi M, Kanda S, Hayashi T, Saito Y, Kanetake H. Predictive values of acute phase reactants, basic fetoprotein and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 2001;58(2):161–4.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cerrahpasa Medical Faculty, Central Biochemistry Laboratory, Istanbul University, Istanbul, Turkey

    Murat Bolayırlı

  2. Cerrahpasa Medical Faculty, Internal Medicine Medical Oncology Department, Istanbul University, Istanbul, Turkey

    Hande Turna & Mustafa Özgüroğlu

  3. Cerrahpasa Medical Faculty, Internal Medicine Department, Istanbul University, Istanbul, Turkey

    Timur Orhanoğlu

  4. Cerrahpasa Medical Faculty, Department of Infectious Disease, Istanbul University, Istanbul, Turkey

    Resat Ozaras

  5. Internal Medicine Medical Oncology Department, Van Yüzüncü Yıl University, Van, Turkey

    Mahmut İlhan

Authors
  1. Murat Bolayırlı
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hande Turna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timur Orhanoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Resat Ozaras
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mahmut İlhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mustafa Özgüroğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mustafa Özgüroğlu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bolayırlı, M., Turna, H., Orhanoğlu, T. et al. C-reactive protein as an acute phase protein in cancer patients. Med Oncol 24, 338–344 (2007). https://doi.org/10.1007/s12032-007-0012-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-007-0012-1

Keywords

Search

Navigation